



# VACCINE ACCESS TEST

Score Summary: Valneva

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. This is the fastest way to end the pandemic. So we want to know: **do world leaders' actions move us closer to, or further from, an equitable outcome?** The Vaccine Access Test provides a framework to answer this question based on the following metrics:

- **Support for & Collaboration with ACT-A:** Has this company collaborated with or provided financial support?
- **Transparency & Knowledge Sharing:** Has the company committed to non-profit and/or tiered pricing? Does this company share relevant knowledge and data to enable widespread access?
- **Multilateral Leadership:** Has leadership expended political capital to motivate cooperation on equity?
- **Deals:** Each deal this company has made to secure promising COVID-19 vaccine candidates is scored individually based on a set of metrics for how well they advance equity.

Each metric is worth up to 3 points and Deal Scores can earn up to 6 points. **Valneva can earn up to 15 points.**

| METRIC   | SCORE | RATIONALE   |
|--|-------|---|
| <b>ACT-A</b><br>                                  | 0     | Valneva has not collaborated with or supported ACT-A.   |
| <b>Transparency &amp; Knowledge Sharing</b><br> | 0     | Valneva has not committed to non-profit and/or tiered pricing and has not committed to sharing knowledge. |
| <b>Multilateral Leadership</b><br>              | 0     | Valneva executives have not used political capital to advance equity globally.                            |
| <b>Deal Score (average)</b>  | 2     | Valneva has completed 1 deal with a country, with a score of 2.   |

Total Score: 2 out of 15

Valneva's actions so far have not demonstrated dedication to equitable outcomes. The company has a long way to go before it is advancing equity.

Valneva can improve its score by collaborating with the ACT-A, committing to non-profit or tiered pricing, and sharing relevant knowledge, intellectual property and data to enable wide-scale production, distribution and use of vaccines, as outlined in the WHO's Solidarity Call to Action.

